Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile

Volume: 16 Issue: 5

Author(s): José Ángel García-Sáenz, Miguel Martín, Pilar Zamora, Ignasi Tusquets, Miguel Ángel Seguí, Ana Santaballa, Pedro Sánchez-Rovira, Manuel Ruiz, Álvaro Rodríguez-Lescure, Arrate Plazaola, Eduardo Martínez de Dueñas, Noelia Martínez-Jáñez, Guillermo López-Vivanco, Rafael López, Juan de la Haba, Antonio González-Martín, Andrés García-Palomo, Elena Galve, Lourdes Calvo, Norberto Batista, Agustí Barnadas, Francisco Ayala de la Peña, José Manuel Aramendía, Isabel Álvarez, Raquel Andrés, Ana Lluch, Antonio Llombart, Javier Cortés, Eva Ciruelos and Emilio Alba

Affiliation:

Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.

Abstract: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.

Cite this article as:

Ángel García-Sáenz José, Martín Miguel, Zamora Pilar, Tusquets Ignasi, Ángel Seguí Miguel, Santaballa Ana, Sánchez-Rovira Pedro, Ruiz Manuel, Rodríguez-Lescure Álvaro, Plazaola Arrate, Martínez de Dueñas Eduardo, Martínez-Jáñez Noelia, López-Vivanco Guillermo, López Rafael, de la Haba Juan, González-Martín Antonio, García-Palomo Andrés, Galve Elena, Calvo Lourdes, Batista Norberto, Barnadas Agustí, Ayala de la Peña Francisco, Manuel Aramendía José, Álvarez Isabel, Andrés Raquel, Lluch Ana, Llombart Antonio, Cortés Javier, Ciruelos Eva and Alba Emilio, Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009615666150817121731